Medical News


Targets Against Hormone-Dependent Breast Cancer

The identification of two cellular receptors that likely contribute to the genesis of hormone-dependent breast cancer points the way to new, highly targeted therapies against the disease, says a team led by researchers at Weill Cornell Medical College in New York City. The finding also helps explain how daily use of medicines such as aspirin might help keep these breast tumors at bay……..

Original post by Health news from medicineworld.org

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists



Related Articles
  • Hormone treatment fights breast cancer
  • Linchpin gene and breast cancer therapies
  • Breast cancer, hormone link even stronger
  • Menopausal hormone treatment and breast cancer linked
  • Pancreatic cancer treatment targets cellular receptors
  • No comments yet. Be the first.

    Leave a reply

    Targets Against Hormone-Dependent Breast Cancer

    The identification of two cellular receptors that likely contribute to the genesis of hormone-dependent breast cancer points the way to new, highly targeted therapies against the disease, says a team led by researchers at Weill Cornell Medical College in New York City. The finding also helps explain how daily use of medicines such as aspirin might help keep these breast tumors at bay……..

    Original post by Health news from medicineworld.org

    Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
    • Digg
    • del.icio.us
    • Netvouz
    • DZone
    • ThisNext
    • MisterWong
    • Wists



    Related Articles
  • Hormone treatment fights breast cancer
  • Linchpin gene and breast cancer therapies
  • Breast cancer, hormone link even stronger
  • Menopausal hormone treatment and breast cancer linked
  • Pancreatic cancer treatment targets cellular receptors
  • No comments yet. Be the first.

    Leave a reply